文献速递心脑血管急症

私人住宅自动体外除颤器的有效性与成本效益:来自增强生存心脏骤停登记处的报告

Effectiveness and Cost-Effectiveness of Automated External Defibrillators in Private Homes: A Report From the Cardiac Arrest Registry to Enhance Survival.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论私人住宅中使用AED仅对可电击心律的心脏骤停改善出院生存(RR 1.26),但按现行价格普遍购置不具成本效益。

该队列研究利用美国增强生存心脏骤停登记处2017年1月至2024年12月的观察性数据,纳入582 536例患者,评估私人住宅中使用AED的有效性,并采用双重差分法分析AED应用与出院生存的因果关系。结果显示,可电击心律患者使用AED后出院生存优于未使用(RR 1.26;95%CI 1.01-1.57),非可电击心律无差异(RR 1.00;95%CI 0.68-1.46)。决策分析模型显示,私人住宅购置AED的增量成本效益比为每质量调整生命年4 481 659美元;在20万美元/质量调整生命年的阈值下,仅当年心脏骤停发生率超过1.3%或AED成本低于65美元(不含旁观者培训成本)时才具成本效益。作者结论认为,私人住宅AED对可电击心律患者有效,但鉴于单户心脏骤停相对罕见,按现行AED价格普遍购买不具成本效益。

要点

  • 可电击心律心脏骤停患者使用AED后出院生存优于未使用(RR 1.26;95%CI 1.01-1.57)。
  • 非可电击心律患者使用AED与未使用的出院生存无显著差异(RR 1.00;95%CI 0.68-1.46)。
  • 私人住宅购置AED的增量成本效益比为每质量调整生命年4 481 659美元。
  • 在20万美元/质量调整生命年阈值下,仅当年心脏骤停发生率超过1.3%或AED成本低于65美元(不含旁观者培训成本)时才具成本效益。
  • 作者结论认为,按现行AED价格,私人住宅普遍购置AED不能视为具成本效益。

适用人群与场景

  • 美国增强生存心脏骤停登记处2017年1月至2024年12月记录的私人住宅心脏骤停患者,共582 536例,其中359 809例(61.8%)为男性,中位年龄65(IQR 52-76)岁。

研究设计与关键结果

  • 研究类型为队列研究,使用美国增强生存心脏骤停登记处2017年1月至2024年12月的观察性数据,共纳入582 536例患者。
  • 可电击心律患者使用AED与未使用相比,出院生存的风险比为1.26(95%CI 1.01-1.57)。
  • 非可电击心律患者使用AED与未使用相比,出院生存的风险比为1.00(95%CI 0.68-1.46)。
  • 双重差分分析结果与上述结果一致。
  • 私人住宅购置AED的增量成本效益比为每质量调整生命年4 481 659美元。
  • 在20万美元/质量调整生命年的成本效益阈值下,当年心脏骤停发生率超过1.3%或AED成本低于65美元(不含旁观者培训成本)时,私人住宅AED才被认为具成本效益。

证据类型、等级与局限

  • 证据类型为队列研究,采用观察性数据和双重差分法分析因果关系,并构建决策分析模型评估成本效益。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,私人住宅AED对可电击心律心脏骤停患者有效,但鉴于单户心脏骤停相对罕见,按现行AED价格普遍购买不具成本效益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Automated external defibrillators (AEDs) have the potential to save lives when used during cardiac arrest. While most cardiac arrests occur at home, there is limited evidence for AED use in private homes.

OBJECTIVE: To determine whether AEDs in private homes are effective and cost-effective.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used observational data from the Cardiac Arrest Registry to Enhance Survival in the US from January 2017 to December 2024 to determine the effectiveness of AEDs when used for cardiac arrests in private homes. A difference-in-difference approach was used to determine the causal relationship between AED application and survival to hospital discharge. A decision-analytic model was then created to evaluate the cost-effectiveness of purchasing an AED in a private home in the US.

EXPOSURE: Application of an AED.

MAIN OUTCOMES AND MEASURES: Survival to hospital discharge and cost-effectiveness.

RESULTS: Of 582 536 included patients, 359 809 (61.8%) were male, and the median (IQR) age was 65 (52-76) years. Survival was better with AED application compared with no AED application in patients with a shockable rhythm (risk ratio, 1.26; 95% CI, 1.01-1.57) but not in those with a nonshockable rhythm (risk ratio, 1.00; 95% CI, 0.68-1.46). Results were consistent in the difference-in-difference analysis. The incremental cost-effectiveness ratio for an AED in a private home was $4 481 659 per quality-adjusted life-year. At a cost-effectiveness threshold of $200 000 per quality-adjusted life-year, AEDs in private homes would be considered cost-effective at a yearly cardiac arrest incidence per person above 1.3% or at an AED cost less than $65 (not including bystander training cost).

CONCLUSIONS AND RELEVANCE: In this study, AEDs in private homes were effective at improving outcomes for patients with cardiac arrest and a shockable rhythm. Given the relative rarity of cardiac arrest at a given home, general purchase of AEDs for individual private homes cannot be considered cost-effective at the current pricing of AEDs.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Andersen LW, Holmberg MJ, Krijkamp E, et al. Effectiveness and Cost-Effectiveness of Automated External Defibrillators in Private Homes: A Report From the Cardiac Arrest Registry to Enhance Survival. JAMA Intern Med. 2026. PMID: 41137600. doi:10.1001/jamainternmed.2025.6123

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。